Table 2. Effect of SAR100842 on ovarian cancer metastasis incidence in two model systemsa.
| Site: | Lesion Depth, where applicable: | Fraction of mice with metastasesb: | |||||
|---|---|---|---|---|---|---|---|
| SKOV3 Model System: | OVCAR5 Model System: | ||||||
| Vehicle: | SAR100842: Day 2 pi |
SAR100842: Day 10 pi |
Vehicle: | SAR100842: Day 2 pi |
SAR100842: Day 10 pi |
||
| Omentum | 13/13 | 10/10 | 10/10 | 9/12 | 8/10 | 7/10 | |
| Liver | Surface | 11/13 | 9/10 | 9/10 | 9/12 | 9/10 | 6/10 |
| Invasive | 1/13 | 0/10 | 0/10 | 2/12 | 2/10 | 1/10 | |
| Diaphragm | Surface | 12/13 | 7/10 | 10/10 | 7/12 | 5/10 | 4/10 |
| Invasive | 12/13 | 7/10 | 10/10 | 7/12 | 5/10 | 2/10 | |
| Lymph Node | Surface | 4/13 | 2/10 | 3/10 | 0/12 | 1/10 | 3/10 |
| Invasive | 0/13 | 0/10 | 0/10 | 0/12 | 0/10 | 0/10 | |
| Kidney | Surface | 5/13 | 1/10 | 2/10 | 0/12 | 0/10 | 0/10 |
| Invasive | 0/13 | 0/10 | 0/10 | 0/12 | 0/10 | 0/10 | |
| Pancreas | Surface | 0/13 | 0/10 | 0/10 | 7/12 | 8/10 | 6/10 |
| Invasive | 0/13 | 0/10 | 0/10 | 5/12 | 5/10 | 4/10 | |
| Peritoneal | Surface | 13/13 | 10/10 | 10/10 | 11/12 | 9/10 | 7/10 |
| Invasive | 0/13 | 0/10 | 0/10 | 0/12 | 0/10 | 0/10 | |
| Ascites | 0/13 | 0/10 | 0/10 | 3/12 | 1/10 | 1/10 | |
aMice were injected intraperitoneally with either SKVO3 or OVCAR5 and treated with either vehicle or 30 mg/kg SAR100842 twice daily starting on either day 2 or day 10 post cell injection (pi). At endpoint, all organs thought to harbor tumor were fixed in 10% NBF before embedding in paraffin for sectioning and H&E staining.
bMetastases were quantified in three sections every 200 μm through each tissue, and characterized as being on the surface of the tissue or invading into the tissue, in consultation with a pathologist.